WESTLAKE VILLAGE, Calif., May 22, 2025 - Arcutis Biotherapeutics Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ZORYVE® (roflumilast) topical foam 0.3%. This approval allows the use of ZORYVE for treating plaque psoriasis of the scalp and body in both adult and pediatric patients aged 12 and older. The once-daily, steroid-free topical foam is now widely available, offering powerful clearance and rapid itch relief without limitations on duration of use. This marks the fifth FDA approval for ZORYVE in under three years, underscoring its significance in addressing the unmet needs in the plaque psoriasis treatment landscape.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.